Scholarlink

<p>Acute severe ulcerative colitis (ASUC) and acute severe Crohn’s disease (CD) flare are potentially life-threatening conditions, for which treatment remains a clinical challenge. Currently available therapeutic options present limited efficacy, with a high rate of colectomy as the final-line treatment method. Therefore, new alternatives of rescue therapy in inflammatory bowel diseases (IBD) are constantly sought. Upadacitinib (UPA), a selective Janus kinase-1 (JAK1) inhibitor, has been approved for the treatment of moderate-to-severe ulcerative colitis (UC) and CD. Interestingly, the most recent data show an increasing off-label use of this medication in the management of acute severe colitis. We present a comprehensive review focusing on rescue therapy with UPA in IBD, both UC and CD. The article examines the outcomes of recent studies evaluating the effectiveness, safety, and tolerability of UPA treatment in adult patients with ASUC and severe CD flare, a new treatment strategy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Upadacitinib as rescue therapy for acute severe ulcerative colitis and severe Crohn’s disease – current knowledge and future directions

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月28日

查看全文
  • Miłosz Caban,
  • Patrycja Dudek,
  • Aleksandra Strigáč,
  • Patrycja Szałwińska,
  • Renata Talar-Wojnarowska

摘要

Acute severe ulcerative colitis (ASUC) and acute severe Crohn’s disease (CD) flare are potentially life-threatening conditions, for which treatment remains a clinical challenge. Currently available therapeutic options present limited efficacy, with a high rate of colectomy as the final-line treatment method. Therefore, new alternatives of rescue therapy in inflammatory bowel diseases (IBD) are constantly sought. Upadacitinib (UPA), a selective Janus kinase-1 (JAK1) inhibitor, has been approved for the treatment of moderate-to-severe ulcerative colitis (UC) and CD. Interestingly, the most recent data show an increasing off-label use of this medication in the management of acute severe colitis. We present a comprehensive review focusing on rescue therapy with UPA in IBD, both UC and CD. The article examines the outcomes of recent studies evaluating the effectiveness, safety, and tolerability of UPA treatment in adult patients with ASUC and severe CD flare, a new treatment strategy.